The Australian Trial in Acute Hepatitis C (ATAHC)

The Australian Trial in Acute Hepatitis C (ATAHC) was an NIH-funded multicentre prospective cohort study of the natural history, and outcomes following treatment with PEG (with or without RBV) in individuals with acute and early chronic HCV infection.

The final results were published in the journal Gastroenterology19.

Between 2004 and 2008, 167 subjects with acute and early chronic HCV infection were enrolled throughout Australia, of whom 111 (76%) subjects with detectable HCV RNA at screening elected to undertake treatment.

  • 57% of the treated population were GT 1
  • the median estimated duration of infection was 25 weeks, indicating that around half the patients had early chronic HCV infection.

  • 33% of subjects were HIV co-infected.

Final analysis of treatment outcomes in the 74 HCV mono-infected subjects who commenced treatment with PEG monotherapy demonstrate: - SVR rates of 55% by intention-to-treat - 72% per-protocol analysis.

Health Issue

Contact Details

For any general enquiries relating to this project, please contact:

Sally von Bibra

Research Officer